Stratosvir Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$331K
- Investors
-
5
Stratosvir General Information
Description
Developer of immunotherapy intended to improve the clinical treatment of solid tumors and their metastases. The company engineers a cancer-killing virus to be used intravenously to deliver medicinal payloads within the tumor to stimulate and reprogram the immune system to attack and destroy cancer, enabling cancer patients to improve their immune system in their fight for effective, safe, non-toxic cancer treatments that increase the quality of life and survival.
Contact Information
Website
www.stratosvir.comCorporate Office
- 46-54 High Street
- Ingatestone CM4 9DW
- England, United Kingdom
Corporate Office
- 46-54 High Street
- Ingatestone CM4 9DW
- England, United Kingdom
Stratosvir Timeline
Stratosvir Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 06-Jun-2024 | $331K | Completed | Generating Revenue | ||
| 2. Accelerator/Incubator | 14-Jul-2023 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 01-Jan-2020 | Completed | Generating Revenue |
Stratosvir Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Stratosvir Patents
Stratosvir Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4453007-A1 | Improved vaccinia virus vectors | Pending | 24-Dec-2021 | ||
| GB-202119008-D0 | Improved vaccinia virus vectors | Pending | 24-Dec-2021 | ||
| GB-2614309-A | Improved vaccinia virus vectors | Pending | 24-Dec-2021 | ||
| JP-2025503515-A | Improved vaccinia virus vectors | Pending | 24-Dec-2021 | ||
| US-20250302997-A1 | Improved vaccinia virus vectors | Pending | 24-Dec-2021 | A61K48/0058 |
Stratosvir Signals
Stratosvir Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Proven Connect | Impact Investing | Minority | ||
| Stevenage Bioscience Catalyst | Accelerator/Incubator | |||
| Cancer Research Technology | Venture Capital | Minority | ||
| Deep Science Ventures | Venture Capital | Minority | ||
| O2h Ventures | Venture Capital | Minority |
Stratosvir FAQs
-
When was Stratosvir founded?
Stratosvir was founded in 2020.
-
Where is Stratosvir headquartered?
Stratosvir is headquartered in Ingatestone, United Kingdom.
-
What is the size of Stratosvir?
Stratosvir has 6 total employees.
-
What industry is Stratosvir in?
Stratosvir’s primary industry is Drug Discovery.
-
Is Stratosvir a private or public company?
Stratosvir is a Private company.
-
What is the current valuation of Stratosvir?
The current valuation of Stratosvir is .
-
What is Stratosvir’s current revenue?
The current revenue for Stratosvir is .
-
How much funding has Stratosvir raised over time?
Stratosvir has raised $331K.
-
Who are Stratosvir’s investors?
Proven Connect, Stevenage Bioscience Catalyst, Cancer Research Technology, Deep Science Ventures, and O2h Ventures have invested in Stratosvir.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process